Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jolly Mazumdar

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Journal of Cellular and Molecular Medicine|November 11, 2009
Hypoxia-inducible factors in stem cells and cancerJolly Mazumdar, Vijay Dondeti, M Celeste Simon
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2006
Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondiiJolly Mazumdar, Emma H Wilson, Kate Masek, et al.
Nature Cell Biology|September 21, 2010
O2 regulates stem cells through Wnt/β-catenin signallingJolly Mazumdar, W Timothy O'Brien, Randall S Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 28, 2010
HIF-2alpha deletion promotes Kras-driven lung tumor developmentJolly Mazumdar, Michele M Hickey, Dhruv K Pant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsAdemi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.
British Journal of Cancer|April 18, 2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Jean-Charles Soria, Sarah P Blagden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaPaolo A Ascierto, David Minor, Antoni Ribas, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Journal of Cellular and Molecular Medicine|November 11, 2009
Hypoxia-inducible factors in stem cells and cancerJolly Mazumdar, Vijay Dondeti, M Celeste Simon
Proceedings of the National Academy of Sciences of the United States of America|August 22, 2006
Apicoplast fatty acid synthesis is essential for organelle biogenesis and parasite survival in Toxoplasma gondiiJolly Mazumdar, Emma H Wilson, Kate Masek, et al.
Nature Cell Biology|September 21, 2010
O2 regulates stem cells through Wnt/β-catenin signallingJolly Mazumdar, W Timothy O'Brien, Randall S Johnson, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 28, 2010
HIF-2alpha deletion promotes Kras-driven lung tumor developmentJolly Mazumdar, Michele M Hickey, Dhruv K Pant, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2015
Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical TrialsAdemi Santiago-Walker, Robert Gagnon, Jolly Mazumdar, et al.
British Journal of Cancer|April 18, 2019
A phase Ib dose-finding, pharmacokinetic study of the focal adhesion kinase inhibitor GSK2256098 and trametinib in patients with advanced solid tumoursGabriel Mak, Jean-Charles Soria, Sarah P Blagden, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 7, 2013
Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanomaPaolo A Ascierto, David Minor, Antoni Ribas, et al.
Pageof 1